Closed-loop Insulin Delivery Systems in Pancreatic Diabetes
NCT ID: NCT06227650
Last Updated: 2024-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2024-02-06
2024-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Assessment of a Closed-loop Insulin Delivery System
NCT01534013
Hybrid Artificial Pancreas in Home Setting
NCT02153190
Closed Loop Context Aware AID
NCT06676657
Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes
NCT07177404
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
NCT03428295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A retrospective observational cohort study in patients will be contucted suffering from secondary pancreatic diabetes in whom this device was implemented in order to observe metabolic and safety outcomes compared to the period before they were treated with hybrid closed-loop system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
hybrid closed loop insulin delivery system
Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hybrid closed loop insulin delivery system
Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting secondary pancreatic diabetes
* Treatment with insulin closed-loop delivery
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Sud Francilien
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfred PENFORNIS, PHD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Sud Francilien
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, Fra, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023/0057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.